Retinal Imaging News
-
Optina Diagnostics Earns Frost & Sullivan’s 2022 NA Technology Innovation Leadership Award
Based on its recent analysis of the North American Hyperspectral Retinal Imaging Industry, Frost & Sullivan recognizes Optina Diagnostics with the 2022 Technology Innovation Leadership Award for offering sophisticated artificial intelligence (AI)-powered Retinal Deep Phenotyping™ solutions. Optina Diagnostics’ comprehensive technology facilitates early and non-invasive diagnostic ...
-
Turning a Great Idea into a Successful Product: ASPIRE
For VisionQuest’s vice president and principal investigator Vinayak Joshi (PhD), the journey from idea to commercial product has led him halfway around the world. Dr. Joshi recently traveled to Malawi, Kenya, Nigeria, and Ghana as part of his efforts to commercialize ASPIRE, his device for the detection and diagnosis of malarial retinopathy. While in Africa, he met with leaders in ...
-
Cerevast Medical Enters Into Strategic Collaboration With Lantheus Medical Imaging for Retinal Vein Occlusion Treatment
Under a development and commercial supply agreement, Lantheus’ microbubble will be used in combination with Cerevast’s ocular ultrasound device to target improving blood flow in occluded retinal veins in the eye. Cerevast’s RVO Technology will combine intravenous administration of Lantheus’ microbubbles with non-invasive ultrasound delivered across the closed eyelid. By ...
-
Augmedics Announces FDA 510K Clearance and U.S. Launch of xvision, the First Augmented Reality Guidance System for Surgery
Augmedics, a pioneer in augmented reality surgical image guidance, has announced U.S. Food and Drug Administration (FDA) 510(k) clearance and the U.S. launch of its groundbreaking xvision Spine system (XVS), the first AR guidance system to be used in surgery. xvision Spine allows surgeons to visualize the 3D spinal anatomy of a patient during surgery as if they had “x-ray vision,” and ...
By Augmedics
-
Optina announces a US$2.1M investment from the Diagnostics Accelerator at the Alzheimer’s Drug Discovery Foundation (ADDF)
A collaborative research initiative supported by ADDF’s Co-Founder Leonard A. Lauder, Bill Gates, Jeff Bezos, MacKenzie Scott, the Dolby family, and the Charles and Helen Schwab Foundation, among others, to advance the most promising early diagnostics for Alzheimer’s disease. Optina, an innovative diagnostics company, leader in retinal imaging, brain health and systemic disease ...
-
Digital Diagnostics Extends Appreciation to CMS for Improving Access to Innovative, Validated Healthcare AI Designed to Eliminate Disparities and Drive Equity
Coralville, Iowa, November 2, 2021 – Digital Diagnostics commends the Centers for Medicare & Medicaid Services (CMS) for recognizing that FDA-cleared, rigorously validated healthcare autonomous artificial intelligence (AI) can address health care disparities and drive health equity. CMS’ CY 2022 Medicare Physician Fee Schedule (MPFS) and CY 2022 Outpatient Prospective Payment ...
-
Optina Diagnostics Closes an Oversubscribed Series-A Round of CA$24.8 million
2021 Optina, an innovative diagnostics company leading the field of Retinal Imaging, Brain Health and Systemic Diseases Diagnostics, announced today the closing of an CA$24.8 million Series A round of funding. Optina’s Retinal Deep Phenotyping™ platform obtained FDA Breakthrough Device Designation status in 2019 for its non-invasive and more accessible test to improve diagnosis ...
-
Notal Vision announces publication of first prospective longitudinal pilot study of daily self-imaging with patient-operated Home OCT in wet AMD patients
Manassas, VA (July 13, 2021) - Notal Vision, Inc. announced today that results from the first prospective longitudinal pilot study of daily, home-based self-imaging with their investigational, patient-operated Home OCT for wet age-related macular degeneration (AMD) patients have been published in Ophthalmology Science.1 The technology is designed to provide retina specialists with remote retinal ...
-
Optos wins Artificial Intelligence in Health and Care Award to support the early detection of diabetes in NHS patients
Optos, a Fife based company and a world-leader in the design and manufacturing of advanced retinal imaging technology, has been awarded NHS funding to accelerate the implementation and validation of Artificial Intelligence (AI) to support the early detection of Diabetes related eye-disease into NHS Diabetic Eye Screening practices. The technology uses a machine learning algorithm to analyse ...
By Optos, Inc.
-
Optina Diagnostics announces a collaborative clinical research study with the Alzheimer Center Amsterdam, Amsterdam UMC
Optina Diagnostics announces today that it has signed an agreement with the Alzheimer Center Amsterdam, part of the Amsterdam University Medical Center to pursue the study of Optina’s Retinal Deep Phenotyping Platform™? in a cohort of 100 subjects. July 29, 2020 Optina Diagnostics announces today that it has signed an agreement with the Alzheimer Center Amsterdam, part of the ...
-
Optina Diagnostics and Wagner Macula Retina Center will Collaborate to Conduct a Clinical Study and Develop a Unique in-community Patient access Program Aimed to Identify the Causes of Memory Loss through Eye Diagnostics
Alzheimer’s awareness month, Optina Diagnostics and Wagner Macula Retina Center will Collaborate to Conduct a Clinical Study and Develop a Unique in-community Patient access Program Aimed to Identify the Causes of Memory Loss through Eye Diagnostics, November 6th 2019 Optina Diagnostics Optina Diagnostics, a world leading company in retinal imaging and artificial intelligence with a vision ...
-
Optos plc, Unveils Silverstone, a Combined Ultra-widefield Retinal Imaging Device and UWF-Guided Swept Source OCT for the Ophthalmic Market
Optos plc, the leading medical retinal imaging company, part of Nikon Corporation, is pleased to announce the launch of Silverstone at the American Academy of Ophthalmology, San Francisco, CA. Silverstone is the first of its kind, combining world-leading ultra-widefield retinal imaging with integrated, image-guided, swept source OCT. Silverstone produces a 200° single capture optomap® ...
By Optos, Inc.
-
Optina Diagnostics and the Montreal Heart Institute Partner to Develop a New Biomarker for Atherosclerosis which could aid in the proper diagnosis of vascular dementia
Do you have senior moments? Are you concerned your memory loss may be a sign of something beyond normal aging? An innovative eye exam is helping physicians answer these questions with confidence. Optina Diagnostics, a world leader in retinal imaging technology and AI with a vision to change mindsets when it comes to brain health and Dr. Jean-Claude Tardif’s research group from the Montreal ...
-
Optina Diagnostics Receives Breakthrough Device Designation from U.S. FDA for a Retinal Imaging Platform to Aid in the Diagnosis of Alzheimer’s Disease
Optina Diagnostics announces today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its retinal imaging platform (CAPRS1/MHRC2). Optina Diagnostics’ platform uses Artificial Intelligence (AI) to analyze the data rich hyperspectral retinal images captured with the MHRC during a simple eye scan. Optina Diagnostics’ platform is intended for ...
-
Eyes on the prize: Optos wins for second year running at UK optical awards
Dunfermline-based Optos, a leading provider of retinal imaging devices, kept its crown at this year’s Optician Awards in Birmingham (30th March), claiming the title of Optical Supplier of the Year for the second time in a row. Epitomising the excellence of the UK optical community, the awards set the bar for industry standards and recognise outstanding performance, achievement and ability. ...
By Optos, Inc.
-
Cerevast Medical Enters Into Strategic Collaboration With Lantheus Medical Imaging for Retinal Vein Occlusion Treatment
Under a development and commercial supply agreement, Lantheus’ microbubble will be used in combination with Cerevast’s ocular ultrasound device to target improving blood flow in occluded retinal veins in the eye. Cerevast’s RVO Technology will combine intravenous administration of Lantheus’ microbubbles with non-invasive ultrasound delivered across the closed eyelid. By ...
-
Optos and Amydis Establish Clinical Alliance to Develop Early Diagnostic Test for Alzheimer’s Disease
Optos Plc, a subsidiary of Nikon Corporation, Japan, and Amydis, Inc. today announced a clinical alliance focused on the development of an eye test by Amydis to detect Alzheimer’s disease. Amydis has developed a pipeline of compounds to detect amyloid proteins in the retina to be visualized with Optos’ market-leading optomap ultra-widefield retinal imaging devices to diagnose ...
By Optos, Inc.
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you